Recent News

• 03.31.2026 - 8-K - Current report
• 03.25.2026 - Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation
• 03.23.2026 - EFFECT - Notice of Effectiveness
• 03.19.2026 - S-3/A - Registration statement under Securities Act of 1933
• 03.17.2026 - ORAGENICS FILES ANNUAL REPORT ON FORM 10-K
• 03.16.2026 - 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.12.2026 - ORAGENICS INITIATES PHASE IIA CLINICAL TRIAL SITE ACTIVATION
• 03.11.2026 - 8-K - Current report
• 03.11.2026 - ORAGENICS EXPLORES EXPANSION OF CNS PLATFORM PURSUING ACQUISTION OF ASSETS IN BRAIN HEALTH, RECOVERY, AND NEUROPROTECTION
• 03.10.2026 - Oragenics Receives HREC Approval for Phase IIa Clinical Trial of ONP-002 as a Treatment for Concussion and Mild Traumatic Brain Injury in Australia

Recent Filings

• 03.20.2026 - EFFECT Notice of Effectiveness
• 03.19.2026 - S-3/A Registration statement under Securities Act of 1933
• 03.16.2026 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.11.2026 - EX-99.1 EX-99.1
• 03.11.2026 - 8-K Current report